uniQure N.V. (QURE)
After hours:
| Previous close | 18.64 |
| Open | 18.52 |
| Bid | 18.40 x 1000 |
| Ask | 19.20 x 800 |
| Day's range | 18.22 - 19.23 |
| 52-week range | 12.52 - 38.80 |
| Volume | |
| Avg. volume | 671,616 |
| Market cap | 894.701M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 2.66 |
| EPS (TTM) | 7.22 |
| Earnings date | 25 July 2022 - 29 July 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.35 |
- Simply Wall St.
Is uniQure (NASDAQ:QURE) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Zacks
uniQure (QURE) Up on Safety Data From Huntington's Disease Study
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.
- GlobeNewswire
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Bar Chart Bar Chart ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. cohort a
